Results 111 to 120 of about 2,101 (161)

Janus kinase inhibitors: another potential for uveitis treatment? [PDF]

Ann Eye Sci
Emami S, Kaisari E, Janetos TM.
europepmc   +1 more source

Real-Life Use of Subcutaneous Biologicals and JAK Inhibitors in IBD Maintenance Therapy: Treatment Continuation, Switching Patterns, and Concomitant Medications. [PDF]

Clin Exp Gastroenterol
Koivusalo M, Jokelainen J, Huhtinen A, Kovac B, Silvola S, Torvinen S, Ylisaukko-Oja T, Arkkila P.   +7 more
europepmc   +1 more source

Upadacitinib in rheumatoid arthritis: progress and challenges. [PDF]

Front Pharmacol
Wang Q, Zhong L, Fu Y, Yang Z.
europepmc   +1 more source

Efficacy of Biologic Agents and Small Molecules for Endoscopic Improvement and Mucosal Healing in Patients with Moderate-to-Severe Ulcerative Colitis: Systematic Review and Meta-Analysis. [PDF]

J Clin Med
Mademlis C, Katsoula A, Koufakis T, Paschos P, Kefas A, Teperikidis L, Theodoridou N, Giouleme O.   +7 more
europepmc   +1 more source

The Impact of PRAC EMA/AIFA Recommendations on the Prescriptions of JAKi and b-DMARDs: Preliminary Results of the Survey from 21 Rheumatological Italian Centers Affiliated with CReI. [PDF]

J Pers Med
Cassarà EAM, Marotto D, Bentivenga C, Martin Martin LS, Baldi G, Carrozzo N, Zicolella R, Terenzi R, Delle Sedie A, Benucci M.   +9 more
europepmc   +1 more source

JAK Inhibitors and Risk of Cancer in IBD Patients. [PDF]

Cancers (Basel)
Bernardi F, Faggiani I, Parigi TL, Zilli A, Allocca M, Furfaro F, Peyrin-Biroulet L, Danese S, D'Amico F.   +8 more
europepmc   +1 more source

Mediators of Filgotinib Treatment Effects in Ulcerative Colitis: Exploring Circulating Biomarkers in the Phase 2b/3 SELECTION Study. [PDF]

Inflamm Bowel Dis
Nakase H, Danese S, Reinisch W, Ritter T, Liang Y, Wendt E, Levesque BG, Yoon OK, Tian Y, Zhuo L, Karouzakis E, Bauer Y, Oortwijn A, Kaise T, Malkov VA, Hibi T.   +15 more
europepmc   +1 more source

Effectiveness and Safety of a Second JAK Inhibitor in Ulcerative Colitis: The J2J Multicentre Study. [PDF]

Aliment Pharmacol Ther
Osty M, Altwegg R, Serrero M, Benezech A, Lecomte A, Cadiot G, Vuitton L, Wampach A, Nancey S, Buisson A, le Berre C, Rouillon C, Gilletta C, Goutorbe F, Fumery M, Hammoudi N, Caillo L, Vidon M, Arab N, Sickersen G, Cavicchi M, Vieujean S, Charkaoui M, Richard N, Wils P, Caron B, Amiot A, Nuzzo A, Laharie D, Kirchgesner J, Uzzan M, GETAID‐J2J group.   +31 more
europepmc   +1 more source

JAK1-selective inhibitors versus pan-JAK inhibitors: comparative real-world study of drug retention in chronic inflammatory arthritis. [PDF]

Ther Adv Musculoskelet Dis
Leon L, Bermejo PP, Laredo L, Peña Pedrosa JA, Benítez Gimenez MT, Freites D, de Miguel C, Abasolo L.   +7 more
europepmc   +1 more source